All Stories

  1. Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions
  2. Externalizing Disorders, Pediatric Anxiety, Autism, and Inflammation-Related Depression
  3. Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder
  4. Schizophrenia, Alcohol Use Disorder, and Stimulant Use Disorder
  5. Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment
  6. Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder
  7. Psychiatric Genetics and Assessing Telehealth Prescribing of Controlled Substances
  8. Adolescent Substance Use and Suicidal Behavior, Internet Overuse, and Shared Genetics Between Problematic Alcohol Use and Other Psychiatric Comorbidities
  9. Depression, Inflammation, and Postpartum Psychosis
  10. Diverse Treatment Strategies and the Valuable Work That Brings Them Forward
  11. Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms
  12. New Developments in the Treatment of Depression, OCD, and Schizophrenia
  13. Tobacco, Alcohol, Heroin, Binge Eating, and Behavioral Addictions
  14. Homelessness, Discrimination, PTSD, Autism, and the Amygdala
  15. Substance Use Disorders
  16. Schizophrenia Spectrum Disorders and Psychosis
  17. Depression: Factors Contributing to Risk and Therapeutic Insights
  18. PTSD, Phobias, Suicide Attempts, and Psychiatric Vulnerabilities
  19. Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems
  20. Advances in Understanding Schizophrenia, ADHD, and ASD
  21. Psychopathology in Youth: Treatment, Parenting, and Intergenerational Transmission
  22. New Insights into Treatments Across the Lifespan
  23. New Developments in Understanding and Treating Opiate and Cannabis Use Disorders
  24. Improving Clinical Outcomes and Informing New Interventions
  25. Adversity and Resilience, Postpartum Depression, Suicide, and Racial/Ethnic Disparities
  26. Substance Use Disorders Are Psychiatric Disorders: Response to Balasanova
  27. Gene expression in the primate orbitofrontal cortex related to anxious temperament
  28. New Insights Into Psychotic Disorders
  29. Stress, Heritability, and Genetic Factors Influencing Depression, PTSD, and Suicidal Behavior
  30. From Postmortem Molecular Studies to Social Determinants of Health Relevant to Racial and Ethnic Disparities
  31. Focusing on Substance Use Disorders, Opioids, and Craving
  32. Treatment Issues Related to the Use of Psychedelics, Trichotillomania, Social Anxiety Disorder, Schizophrenia, and Opioid Use Disorder
  33. Insights From Genetic, Neuroimaging, and Behavioral Neuroscience Studies
  34. Insights and Advances Into Treatments for Major Depression
  35. Race-Related Disparities in Childhood Adversity, Trauma, and Stress-Related Psychopathology
  36. Childhood- and Neurodevelopment-Related Psychiatric Disorders
  37. New Therapeutic Approaches Involving Psychopharmacology, Digital Technology, and fMRI Neurofeedback
  38. Polygenic Risk Scores and Genetics in Psychiatry
  39. Opioid Use Disorder, Cannabis Use Disorder, and a Mindfulness Intervention Affecting Pain-Related Neural Substrates
  40. Combining Molecular and Neuroimaging Measures to Understand Psychopathology and Inform New Treatment Development
  41. The American Journal of Psychiatry’s Efforts Toward Eliminating Racism, Social Injustice, Health Care Inequities, and Publication Biases
  42. Neurodevelopmental and Neurodegenerative Illnesses: Autism, Fragile X Syndrome, Parkinson’s Disease, and Dementia
  43. Neuroscientific Advances Supporting New Treatments for Major Depression
  44. Structural Racism and the Imperative to Eliminate Mental Health Disparities
  45. From the Early Emergence of Psychiatry to Stem Cells and Neural Organoids
  46. Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia
  47. Insights Into the Genomic Underpinnings of Psychopathology
  48. Spanning Treatment Modalities: Psychotherapy, Psychopharmacology, and Neuromodulation
  49. Alcohol and Cannabis Use Disorders
  50. New Insights Into Major Depression and the Treatment of Bipolar Depression
  51. Adversity, Trauma, Suicide, and Alzheimer’s Disease
  52. Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment
  53. Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities
  54. Understanding the Value and Limitations of MRI Neuroimaging in Psychiatry
  55. Impacts of Structural Racism, Socioeconomic Deprivation, and Stigmatization on Mental Health
  56. COVID-19 and Stress-Related Disorders
  57. Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry
  58. Anxiety, Depression, and Suicide in Youth
  59. Improving Treatment Outcomes Includes Increasing the Diversity of the Psychiatric Workforce
  60. Trauma, Resilience, Anxiety Disorders, and PTSD
  61. Genes, Cells, and Neural Circuits Relevant to OCD and Autism Spectrum Disorder
  62. Molecules and Circuits Implicated in Schizophrenia Provide Leads for Novel Treatments
  63. Substance Use Disorders and Addiction: Mechanisms, Trends, and Treatment Implications
  64. Insights Into Suicide and Depression
  65. Childhood and Adolescent Neurodevelopmental Disorders
  66. The American Journal of Psychiatry’s Commitment to Combat Racism, Social Injustice, and Health Care Inequities
  67. Advances in Understanding and Treating Mood Disorders
  68. COVID-19, Substance Use, Anorexia Nervosa, 22q11.2 Deletion Syndrome, and Stress
  69. New Findings Related to Cognition, Intellectual Disability, Dementia, and Autism
  70. The Critical Relationship Between Anxiety and Depression
  71. Psychotic Experiences, Cognitive Decline, and Genetic Vulnerabilities in Relation to Developing Psychotic Disorders
  72. Novel Insights Into Pathological Anxiety and Anxiety-Related Disorders
  73. Treating Substance Use Disorders, Binge Eating, and Depression, and Identifying Factors Underlying Psychosis Risk
  74. Early-Life Environmental Factors Impacting the Development of Psychopathology
  75. Prefrontal Cortical and Limbic Circuit Alterations in Psychopathology
  76. Developing Innovative and Novel Treatment Strategies
  77. Gaining Ground on Schizophrenia: Conceptualizing How to Use Neuroimaging and Genomics in Its Diagnosis and Treatment
  78. Integrating Clinical Psychiatry With Behavioral Neuroscience: Reflections and a Call for Papers
  79. Psychiatric Genetics: Scientific Advances and Clinical Challenges
  80. Using Neuroimaging to Characterize Brain Alterations Associated With Psychopathology
  81. Developing Novel Psychopharmacological Strategies and Therapeutics
  82. New Insights Into the Mechanisms of Ketamine’s Antidepressant Effects: Understanding the Role of VEGF in Mediating Plasticity Processes
  83. Improving the Lives of Patients With Major Depression by Focusing on New Treatment Approaches
  84. Optimizing the Efficacy of Psychotherapy, Cognitive Training, and Internet Interventions
  85. Altered Uncinate Fasciculus Microstructure in Childhood Anxiety Disorders in Boys But Not Girls
  86. New Insights Highlighting Neurodevelopmental Issues That Predispose to Childhood and Adolescent Psychopathology
  87. New Findings Relevant to Substance Use Disorders
  88. An Introduction and Vision
  89. Corticotropin-Releasing Hormone Binding Protein: Stress, Psychopathology, and Antidepressant Treatment Response